Lisa Olson, Ph.D.

Lisa Olson, Ph.D.

Former Chief Scientific OfficeratDianthus Therapeutics, Inc. /DE/· In proxies 2022–2023

Pay in FY2023+15% from the year before · Dianthus Therapeutics, Inc. /DE/ stock +64.6% the same year

Lisa Olson, Ph.D. was paid $1.1M in FY2023 (Dec), up 15%. Dianthus Therapeutics, Inc. /DE/ stock rose 64.6% that year.

Pay$100 in the stock at the end of FY21 → $15
Pay is from the Summary Compensation Table of each Dianthus Therapeutics, Inc. /DE/ proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Dianthus Therapeutics, Inc. /DE/Public company · 4 yr
    • Former Chief Scientific Officer2022 – Present · 4 yrStock in role +11%

Roles come from the proxy statements of each company.

Activity

Two people shown as one, or a wrong number?